Cue Biopharma/$CUE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cue Biopharma
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
- Ticker
- $CUE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 29
- Headquarters
- Boston, United States
- Website
- www.cuebiopharma.com
Cue Biopharma Metrics
BasicAdvanced
$136M
-
-$36.22
2.47
-
Price and volume
Market cap
$136M
Beta
2.47
52-week high
$45.50
52-week low
$10.76
Average daily volume
164K
Financial strength
Current ratio
1.255
Quick ratio
1.074
Long term debt to equity
0.627
Total debt to equity
1.332
Interest coverage (TTM)
-508.47%
Profitability
EBITDA (TTM)
-97.284
Gross margin (TTM)
-99.15%
Net profit margin (TTM)
-435.82%
Operating margin (TTM)
-261.97%
Effective tax rate (TTM)
-0.31%
Revenue per employee (TTM)
$1,300,000
Management effectiveness
Return on assets (TTM)
-172.66%
Return on equity (TTM)
-1,603.48%
Valuation
Price to revenue (TTM)
2.245
Price to book
42.24
Price to tangible book (TTM)
42.24
Price to free cash flow (TTM)
-1.685
Free cash flow yield (TTM)
-59.34%
Free cash flow per share (TTM)
-11.073
Growth
Revenue change (TTM)
354.44%
Earnings per share change (TTM)
129.24%
3-year revenue growth (CAGR)
176.10%
3-year earnings per share growth (CAGR)
-1.52%
What the Analysts think about Cue Biopharma
Analyst ratings (Buy, Hold, Sell) for Cue Biopharma stock.
Analyst projections of the future price of Cue Biopharma stock.
Cue Biopharma Financial Performance
Revenues and expenses
Cue Biopharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cue Biopharma News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.